The global market for opioid-induced constipation (OIC) will increase significantly from $144.42 million in 2012 to $1.98 billion by 2017, at a compound annual growth rate (CAGR) of 31.9%, forecasts research and consulting firm GlobalData.
According to the company’s latest report, the European Union has contributed to the majority of these sales, generating an estimated $75.4 million in 2012. While Germany was the largest market in the same year, with a share of $41.5 million, the majority of sales will come from the USA in 2017, thanks to its possession of more than 90% of the market with a share of $1.79 billion.
PAMORA therapies will drive growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze